Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD.

PubWeight™: 4.12‹?› | Rank: Top 1%

🔗 View Article (PMID 15472670)

Published in Gastrointest Endosc on October 01, 2004

Authors

Marco Daperno1, Geert D'Haens, Gert Van Assche, Filip Baert, Philippe Bulois, Vincent Maunoury, Raffaello Sostegni, Rodolfo Rocca, Angelo Pera, Annemie Gevers, Jean-Yves Mary, Jean-Frédéric Colombel, Paul Rutgeerts

Author Affiliations

1: Gastroenterology Unit, Ospedale Mauriziano Umberto I, Torino, Italy.

Associated clinical trials:

GIS-SUSANTI-TNF-2015 (Anti-TNF Discontinuation ) | NCT02994836

Study of the Role of Pomegranate Juice Ellagitannins in the Modulation of Inflammation in Inflammatory Bowel Diseases (POME2016) | NCT03000101

Identification of Predictive Biomarkers for Response to Biologic Therapies in Inflammatory Bowel Disease (BioIBD) | NCT03885713

Articles citing this

(truncated to the top 100)

Canadian Association of Gastroenterology consensus guidelines on safety and quality indicators in endoscopy. Can J Gastroenterol (2012) 3.15

The Relationship Among Perceived Stress, Symptoms, and Inflammation in Persons With Inflammatory Bowel Disease. Am J Gastroenterol (2015) 2.51

Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn's disease. Gut (2006) 2.41

Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol (2009) 2.27

Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis (2010) 2.20

Assessment and validation of the new capsule endoscopy Crohn's disease activity index (CECDAI). Dig Dis Sci (2007) 1.96

Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut (2007) 1.90

Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut (2007) 1.62

Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis (2006) 1.44

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol (2015) 1.44

Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease. Dig Dis Sci (2011) 1.30

Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut (2006) 1.18

Evaluation of inflammatory activity in Crohn's disease and ulcerative colitis. World J Gastroenterol (2012) 1.16

Emerging inflammatory bowel disease in saudi outpatients: a report of 693 cases. Saudi J Gastroenterol (2013) 1.14

Risk of postoperative recurrence and postoperative management of Crohn's disease. World J Gastroenterol (2011) 1.12

Utility of faecal calprotectin analysis in adult inflammatory bowel disease. World J Gastroenterol (2012) 1.12

Mucosal healing in inflammatory bowel disease-a true paradigm of success? Gastroenterol Hepatol (N Y) (2012) 1.08

Distribution of enteric glia and GDNF during gut inflammation. BMC Gastroenterol (2011) 1.01

Exclusive enteral nutrition induces early clinical, mucosal and transmural remission in paediatric Crohn's disease. J Gastroenterol (2013) 1.01

Looking beyond symptom relief: evolution of mucosal healing in inflammatory bowel disease. Therap Adv Gastroenterol (2011) 0.99

Impact of capsule endoscopy on management of inflammatory bowel disease: a single tertiary care center experience. Inflamm Bowel Dis (2011) 0.96

Comparison of three magnetic resonance enterography indices for grading activity in Crohn's disease. J Gastroenterol (2016) 0.96

Relationship between serum infliximab trough levels and endoscopic activities in patients with Crohn's disease under scheduled maintenance treatment. J Gastroenterol (2013) 0.94

Role of endoscopy in predicting the disease course in inflammatory bowel disease. World J Gastroenterol (2010) 0.93

Frequency and prognostic role of mucosal healing in patients with Crohn's disease and ulcerative colitis after one-year of biological therapy. World J Gastroenterol (2014) 0.92

Measuring disease activity in Crohn's disease: what is currently available to the clinician. Clin Exp Gastroenterol (2014) 0.92

Soluble ST2: a new and promising activity marker in ulcerative colitis. World J Gastroenterol (2011) 0.91

Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn's disease. Clin Exp Immunol (2013) 0.91

Comparison of six different calprotectin assays for the assessment of inflammatory bowel disease. United European Gastroenterol J (2014) 0.90

Anastomotic recurrence of Crohn's disease after ileocolic resection: comparison of MR enteroclysis with endoscopy. Eur Radiol (2008) 0.88

Central endoscopy reads in inflammatory bowel disease clinical trials: The role of the imaging core lab. Gastroenterol Rep (Oxf) (2014) 0.88

MRI in Crohn's disease--current and future clinical applications. Nat Rev Gastroenterol Hepatol (2011) 0.88

Usefulness of C-reactive protein as a disease activity marker in Crohn's disease according to the location of disease. Gut Liver (2015) 0.88

Limitations in assessment of mucosal healing in inflammatory bowel disease. World J Gastroenterol (2010) 0.88

Adalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trial. Clin Exp Gastroenterol (2013) 0.87

Rapid Fecal Calprotectin Test and Symptom Index in Monitoring the Disease Activity in Colonic Inflammatory Bowel Disease. Dig Dis Sci (2017) 0.85

Utility of neutrophil Fcγ receptor I (CD64) index as a biomarker for mucosal inflammation in pediatric Crohn's disease. Inflamm Bowel Dis (2014) 0.84

Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn's Disease. Case Rep Gastroenterol (2012) 0.84

Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice. J Crohns Colitis (2015) 0.84

Correlations between endoscopic and clinical disease activity indices in intestinal Behcet's disease. World J Gastroenterol (2012) 0.84

Contrast Enhanced Abdominal Ultrasound in the Assessment of Ileal Inflammation in Crohn's Disease: A Comparison with MR Enterography. PLoS One (2015) 0.83

Mechanisms, Management, and Treatment of Fibrosis in Patients with Inflammatory Bowel Diseases. Gastroenterology (2016) 0.83

Efalizumab, a human monoclonal anti-CD11a antibody, in the treatment of moderate to severe Crohn's Disease: an open-label pilot study. Dig Dis Sci (2010) 0.83

Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies. PLoS One (2014) 0.83

Is faecal calprotectin equally useful in all Crohn's disease locations? A prospective, comparative study. Arch Med Sci (2015) 0.82

Defective expression of SIRT1 contributes to sustain inflammatory pathways in the gut. Mucosal Immunol (2014) 0.81

Low-dose azathioprine effectively improves mucosal healing in Chinese patients with small bowel Crohn's disease. J Dig Dis (2014) 0.81

The role of mucosal healing in the treatment of patients with inflammatory bowel disease. Curr Treat Options Gastroenterol (2014) 0.81

Bamboo joint-like appearance of the stomach: a stable endoscopic landmark for Crohn's disease regardless of anti-tumor necrosis factor alpha treatment. Med Sci Monit (2014) 0.81

Relationship between neutrophil gelatinase-associated lipocalin (NGAL) levels and inflammatory bowel disease type and activity. Dig Dis Sci (2013) 0.81

Two-Year Outcomes After Exclusive Enteral Nutrition Induction Are Superior to Corticosteroids in Pediatric Crohn's Disease Treated Early with Thiopurines. Dig Dis Sci (2015) 0.80

Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial. BMJ Open (2014) 0.80

IL-1β promotes Th17 differentiation by inducing alternative splicing of FOXP3. Sci Rep (2015) 0.80

Intestinal protein expression profile identifies inflammatory bowel disease and predicts relapse. Int J Clin Exp Pathol (2013) 0.80

Predicting Endoscopic Crohn's Disease Activity Before and After Induction Therapy in Children: A Comprehensive Assessment of PCDAI, CRP, and Fecal Calprotectin. Inflamm Bowel Dis (2015) 0.80

Serum Levels of Lipopolysaccharide and 1,3-β-D-Glucan Refer to the Severity in Patients with Crohn's Disease. Mediators Inflamm (2015) 0.80

Inflammatory Bowel Disease Patients' Willingness to Accept Medication Risk to Avoid Future Disease Relapse. Am J Gastroenterol (2015) 0.79

Mucosal healing did not predict sustained clinical remission in patients with IBD after discontinuation of one-year infliximab therapy. PLoS One (2014) 0.79

Measuring structural damage in Crohn's disease. Gastroenterol Hepatol (N Y) (2013) 0.79

Serial intralesional injections of infliximab in small bowel Crohn's strictures are feasible and might lower inflammation. United European Gastroenterol J (2014) 0.79

Recent trends in diagnostic techniques for inflammatory bowel disease. Korean J Intern Med (2015) 0.79

Crohn's disease: the first visit. Gastroenterol Hepatol (N Y) (2011) 0.79

Human cytomegalovirus and Epstein-Barr virus infection in inflammatory bowel disease: need for mucosal viral load measurement. World J Gastroenterol (2015) 0.79

Fecal Lactoferrin: Reliable Biomarker for Intestinal Inflammation in Pediatric IBD. Gastroenterol Res Pract (2015) 0.79

Serrated adenoma prevalence in inflammatory bowel disease surveillance colonoscopy, and characteristics revealed by chromoendoscopy and virtual chromoendoscopy. Can J Gastroenterol Hepatol (2014) 0.79

Pre- and posttherapy assessment of intestinal soluble mediators in IBD: where we stand and future perspectives. Mediators Inflamm (2013) 0.79

Infliximab preferentially induces clinical remission and mucosal healing in short course Crohn's disease with luminal lesions through balancing abnormal immune response in gut mucosa. Mediators Inflamm (2015) 0.78

Lamina propria macrophage phenotypes in relation to Escherichia coli in Crohn's disease. BMC Gastroenterol (2015) 0.78

Dendritic cells from Crohn's disease patients show aberrant STAT1 and STAT3 signaling. PLoS One (2013) 0.78

Utility of the diffusion-weighted imaging for activity evaluation in Crohn's disease patients underwent magnetic resonance enterography. BMC Gastroenterol (2015) 0.78

Therapeutic effect of intensive granulocyte and monocyte adsorption apheresis combined with thiopurines for steroid- and biologics-naïve Japanese patients with early-diagnosed Crohn's disease. BMC Gastroenterol (2014) 0.78

Targeting mucosal healing in Crohn's disease. Gastroenterol Hepatol (N Y) (2011) 0.78

Diagnostic yield of endomicroscopy for dysplasia in primary sclerosing cholangitis associated inflammatory bowel disease: a feasibility study. Endosc Int Open (2016) 0.77

Computed tomography enterography and magnetic resonance enterography: the future of small bowel imaging. Clin Colon Rectal Surg (2008) 0.77

Accuracy of Rapid Fecal Calprotectin Test in Monitoring Inflammatory Bowel Diseases Under Treatment with TNFα Antagonists. Dig Dis Sci (2014) 0.77

Assessment of Disease Activity in Small Bowel Crohn's Disease: Comparison between Endoscopy and Magnetic Resonance Enterography Using MRIA and Modified MRIA Score. Gastroenterol Res Pract (2015) 0.77

Are faecal markers good indicators of mucosal healing in inflammatory bowel disease? World J Gastroenterol (2015) 0.77

Protocol for a prospective multicentre cohort study to develop and validate two new outcome measures for patients with inflammatory bowel disease. BMJ Open (2013) 0.77

Magnetic resonance enterographic predictors of one-year outcome in ileal and ileocolonic Crohn's disease treated with anti-tumor necrosis factor antibodies. Sci Rep (2015) 0.77

Current best practice for disease activity assessment in IBD. Nat Rev Gastroenterol Hepatol (2016) 0.77

Pivotal Role of Carbohydrate Sulfotransferase 15 in Fibrosis and Mucosal Healing in Mouse Colitis. PLoS One (2016) 0.77

Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease. World J Gastroenterol (2015) 0.77

Ultrasound and MRI predictors of surgical bowel resection in pediatric Crohn disease. Pediatr Radiol (2016) 0.77

Taking Crohn's disease personally. Rambam Maimonides Med J (2013) 0.76

The influence of anti-TNF therapy on the magnetic resonance enterographic parameters of Crohn's disease activity. Abdom Imaging (2015) 0.76

Clinical Activity and Quality of Life Indices Are Valid Across Ulcerative Colitis But Not Crohn's Disease Phenotypes. Dig Dis Sci (2016) 0.76

Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy. World J Gastrointest Pathophysiol (2016) 0.76

Rapid fecal calprotectin testing to assess for endoscopic disease activity in inflammatory bowel disease: A diagnostic cohort study. Saudi J Gastroenterol (2015) 0.75

Implementation of the simple endoscopic activity score in crohn's disease. Saudi J Gastroenterol (2016) 0.75

Modified Side-To-Side Isoperistaltic Strictureplasty over the Ileocaecal Valve: An Alternative to Ileocaecal Resection in Extensive Terminal Ileal Crohn's Disease. J Crohns Colitis (2015) 0.75

Usefulness of Endoscopic Indices in Determination of Disease Activity in Patients with Crohn's Disease. Gastroenterol Res Pract (2016) 0.75

Searching for the delta: 5-aminosalicylic Acid therapy for Crohn's disease. Gastroenterol Hepatol (N Y) (2011) 0.75

Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn's disease: correlation with SES-CD and clinical-biological markers. BMC Med Imaging (2016) 0.75

Preventing Collateral Damage in Crohn's Disease: The Lémann Index. J Crohns Colitis (2016) 0.75

The Correlation of Serum IL-12B Expression With Disease Activity in Patients With Inflammatory Bowel Disease. Medicine (Baltimore) (2016) 0.75

Non-surgical porto-mesenteric vein thrombosis is associated with worse long-term outcomes in inflammatory bowel diseases. Gastroenterol Rep (Oxf) (2015) 0.75

Validation and Optimization of an Ex Vivo Assay of Intestinal Mucosal Biopsies in Crohn's Disease: Reflects Inflammation and Drug Effects. PLoS One (2016) 0.75

Monocyte-derived dendritic cells from Crohn's disease patients exhibit decreased ability to activate T helper type 17 responses in memory cells. Clin Exp Immunol (2014) 0.75

Computed Tomography and Magnetic Resonance Enterography in Crohn's Disease: Assessment of Radiologic Criteria and Endpoints for Clinical Practice and Trials. Inflamm Bowel Dis (2016) 0.75

Validation of gene expression biomarker analysis for biopsy-based clinical trials in Crohn's disease. Inflamm Bowel Dis (2015) 0.75

Articles by these authors

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet (2008) 30.20

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med (2009) 22.23

Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet (2010) 17.38

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14

Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med (2010) 12.35

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet (2008) 10.47

Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16

Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet (2007) 8.63

Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med (2003) 8.49

Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet (2011) 7.98

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88

Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77

Natalizumab for active Crohn's disease. N Engl J Med (2003) 6.44

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology (2006) 6.36

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med (2005) 6.33

Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut (2011) 6.08

High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology (2004) 5.94

Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology (2011) 5.38

Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med (2005) 5.36

CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet (2002) 5.31

Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet (2012) 5.12

Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet (2008) 5.05

Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med (2013) 4.75

Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med (2012) 4.41

Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med (2007) 4.39

VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet (2003) 4.19

Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med (2007) 4.07

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology (2005) 4.06

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology (2008) 3.98

Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med (2013) 3.98

Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis (2012) 3.89

Common variants at five new loci associated with early-onset inflammatory bowel disease. Nat Genet (2009) 3.82

Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology (2011) 3.81

Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology (2014) 3.77

Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology (2009) 3.73

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis (2012) 3.69

A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology (2006) 3.68

The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis (2009) 3.66

Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology (2013) 3.45

Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology (2004) 3.40

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology (2008) 3.36

Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. Gut (2011) 3.36

The yield of upper gastrointestinal endoscopy in patients with suspected reflux-related chronic ear, nose, and throat symptoms. Am J Gastroenterol (2004) 3.25

Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. Nat Genet (2010) 3.22

Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA (2008) 3.09

Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology (2011) 3.08

Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology (2003) 3.05

Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol (2004) 2.99

Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology (2011) 2.96

Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology (2012) 2.95

Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol (2002) 2.94

Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology (2006) 2.91

Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis (2007) 2.89

Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. Gut (2011) 2.87

A novel intravenous iron formulation for treatment of anemia in inflammatory bowel disease: the ferric carboxymaltose (FERINJECT) randomized controlled trial. Am J Gastroenterol (2008) 2.71

A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology (2005) 2.70

Common variants in the NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet (2008) 2.67

Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology (2003) 2.59

Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut (2011) 2.58

The value of serologic markers in indeterminate colitis: a prospective follow-up study. Gastroenterology (2002) 2.58

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis (2012) 2.55

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut (2007) 2.53

CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J Clin Invest (2007) 2.44

Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol (2008) 2.44

Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology (2008) 2.39

Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology (2003) 2.37

Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol (2009) 2.36

Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis (2009) 2.33

Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol (2009) 2.27

Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology (2009) 2.26